Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice

References

• Byrd JC, Brown JR, O'Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371:213–223.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369:32–42.
   PubMed Web of Science ®Google Scholar
• Chanan-Khan A, Cramer P, Demirkan F, et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol. 2016;17:200–211. [https://doi.org/WorldCat]
   PubMed Web of Science ®Google Scholar
• Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med. 2015;373:2425–2437.
   PubMed Web of Science ®Google Scholar
• Farooqui MZ, Valdez J, Martyr S, et al. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. Lancet Oncol. 2015;16:169–176.
   PubMed Web of Science ®Google Scholar
• Burger JA, Keating MJ, Wierda WG, et al. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2014;15:1090–1099.
   PubMed Web of Science ®Google Scholar
• Niel N, Rechencq E, Muller A, et al. Synthesis and contractile activity of new pseudopeptido and thioaromatic analogues of leukotriene D4. Prostaglandins. 1992;43:45–54.
   PubMed Web of Science ®Google Scholar
• Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138:103–141.
   PubMed Web of Science ®Google Scholar
• Scheers E, Leclercq L, de Jong J, et al. Absorption, metabolism, and excretion of oral 14C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men. Drug Metab Dispos. 2015;43:289–297.
   PubMed Web of Science ®Google Scholar
• de Jong J, Skee D, Murphy J, et al. Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants. Pharmacol Res Perspect. 2015;3:e00156.
   PubMed Web of Science ®Google Scholar
• Sparreboom A, Cox MC, Acharya MR, et al. Herbal remedies in the United States: potential adverse interactions with anticancer agents. J Clin Oncol. 2004;22:2489–2503.
   PubMed Web of Science ®Google Scholar
• Zhou S, Gao Y, Jiang W, et al. Interactions of herbs with cytochrome P450. Drug Metab Rev. 2003;35:35–98.
   PubMed Web of Science ®Google Scholar
• IMBRUVICA^® [package insert]. Sunnyvale, CA: Pharmacyclics. Inc.,vol. 2016; February 2014.
   Google Scholar
• Kamel S, Horton L, Ysebaert L, et al. Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation. Leukemia. 2015;29:783–787.
   PubMed Web of Science ®Google Scholar
• Levade M, David E, Garcia C, et al. Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions. Blood. 2014;124:3991–3995.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Drug development and drug interactions: table of substrates, inhibitors and inducers. 2016. Availabe at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm [Accessed February 12, 2016].
   Google Scholar
• Flockhart DA. Drug interactions: cytochrome P450 drug interaction table. Indiana University School of Medicine, 2007. Available at: http://medicine.iupui.edu/clinpharm/ddis/clinical-table/ [Accessed February 12, 2016].
   Google Scholar
• Teo YL, Ho HK, Chan A. Metabolism-related pharmacokinetic drug − drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations. Br J Clin Pharmacol. 2015;79:241–253.
   PubMed Web of Science ®Google Scholar
• Wu P, Nielsen TE, Clausen MH. FDA-approved small-molecule kinase inhibitors. Trends Pharmacol Sci. 36:422–439.
   PubMed Web of Science ®Google Scholar
• Bowlin SJ, Xia F, Wang W, et al. Twelve-month frequency of drug-metabolizing enzyme and transporter-based drug-drug interaction potential in patients receiving oral enzyme-targeted kinase inhibitor antineoplastic agents. Mayo Clin Proc. 2013;88:139–148.
   PubMed Web of Science ®Google Scholar
• Riechelmann RP, Del Giglio A. Drug interactions in oncology: how common are they? Ann Oncol. 2009;20:1907–1912.
   PubMed Web of Science ®Google Scholar
• Scripture CD, Figg WD. Drug interactions in cancer therapy. Nat Rev Cancer. 2006;6:546–558.
   PubMed Web of Science ®Google Scholar
• van Leeuwen RW, Brundel DH, Neef C, et al. Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugs. Br J Cancer. 2013;108:1071–1078.
   PubMed Web of Science ®Google Scholar
• McKee M, Frei BL, Garcia A, et al. Impact of clinical pharmacy services on patients in an outpatient chemotherapy academic clinic. J Oncol Pharm Pract. 2011;17:387–394.
   PubMedGoogle Scholar
• Ruder AD, Smith DL, Madsen MT, 3rd, et al. Is there a benefit to having a clinical oncology pharmacist on staff at a community oncology clinic? J Oncol Pharm Pract. 2011;17:425–432.
   PubMedGoogle Scholar
• Barr PM, Brown JR, Hillmen P, et al. Dose adherence and baseline exposure analysis of the ibrutinib 420 mg dose administered to patients with previously treated chronic lymphocytic leukemia (CLL). J Clin Oncol. 2015;33(suppl):Abstr 7012.
   Google Scholar
• Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370:997–1007.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Harrington B, O'Brien S, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374:323–332.
   PubMed Web of Science ®Google Scholar
• Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374:311–322.
   PubMed Web of Science ®Google Scholar
• Yap KY, Raaj S, Chan A. OncoRx-IQ: a tool for quality assessment of online anticancer drug interactions. Int J Qual Health Care. 2010;22:93–106.
   PubMed Web of Science ®Google Scholar